Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buspirone/Zolmitriptan (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Bukwang Pharmaceutical

Most Recent Events

  • 12 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 15 Jun 2015 According to a Bukwang Pharma and Contera Pharma media release, the first patient was dosed for this study in June 2015 and the company has planned to complete the dosing of at least 25 patients by first quarter 2016 followed by reporting later in H1 2016.
  • 27 May 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top